Price
$0.83
Increased by +1.82%
Dollar volume (20D)
506.56 K
ADR%
16.91
Shares float
24.52 M
Shares short
1.22 M [4.97%]
Shares outstanding
33.19 M
Market cap
27.22 M
Beta
0.66
Price/earnings
N/A
20D range
0.36 0.90
50D range
0.24 0.90
200D range
0.24 3.98

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.

The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.

It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease.

Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 23, 25 -0.58
Increased by +19.44%
-0.31
Decreased by -87.10%
Mar 17, 25 -0.62
Increased by +26.19%
-0.70
Increased by +11.43%
Nov 6, 24 -0.72
Increased by +1.37%
-0.64
Decreased by -12.50%
Aug 7, 24 -0.59
Increased by +29.76%
-0.83
Increased by +28.92%
May 8, 24 -0.72
Increased by +17.24%
-0.85
Increased by +15.29%
Mar 19, 24 -0.84
Increased by +40.43%
-0.83
Decreased by -1.20%
Nov 8, 23 -0.73
Increased by +44.27%
-0.91
Increased by +19.78%
Aug 8, 23 -0.84
Increased by +36.84%
-0.90
Increased by +6.67%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 25 0.00
Decreased by N/A%
-17.56 M
Increased by +19.56%
Decreased by N/A%
Decreased by N/A%
Dec 31, 24 0.00
Decreased by N/A%
-18.66 M
Increased by +25.86%
Decreased by N/A%
Decreased by N/A%
Sep 30, 24 0.00
Decreased by N/A%
-21.73 M
Increased by +1.25%
Decreased by N/A%
Decreased by N/A%
Jun 30, 24 0.00
Decreased by N/A%
-17.77 M
Increased by +29.78%
Decreased by N/A%
Decreased by N/A%
Mar 31, 24 0.00
Decreased by N/A%
-21.83 M
Increased by +17.07%
Decreased by N/A%
Decreased by N/A%
Dec 31, 23 0.00
Decreased by N/A%
-25.17 M
Increased by +33.68%
Decreased by N/A%
Decreased by N/A%
Sep 30, 23 0.00
Decreased by N/A%
-22.00 M
Increased by +44.18%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-25.30 M
Increased by +36.64%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY